Artivion’s (AORT) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Artivion (NYSE:AORT) in a research note published on Monday morning, Marketbeat.com reports. Needham & Company LLC currently has a $44.00 target price on the stock.

A number of other analysts also recently weighed in on the stock. LADENBURG THALM/SH SH upgraded shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price target on the stock in a research report on Friday, April 10th. Stifel Nicolaus set a $45.00 target price on shares of Artivion in a research note on Monday, June 1st. Weiss Ratings lowered shares of Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, June 8th. Citizens Jmp reduced their price target on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research report on Friday, May 8th. Finally, Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $44.17.

Artivion Stock Performance

Artivion stock opened at $25.15 on Monday. The company has a market cap of $1.22 billion, a PE ratio of 104.80 and a beta of 1.26. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. Artivion has a 1 year low of $19.16 and a 1 year high of $48.25. The company’s 50-day moving average is $22.59 and its two-hundred day moving average is $32.50.

Insider Buying and Selling at Artivion

In related news, SVP Andrew M. Green sold 44,001 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the transaction, the senior vice president directly owned 60,259 shares in the company, valued at approximately $1,247,361.30. The trade was a 42.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Verition Fund Management LLC lifted its position in Artivion by 1.6% in the 3rd quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock valued at $716,000 after acquiring an additional 274 shares in the last quarter. Entropy Technologies LP boosted its stake in Artivion by 6.0% in the 4th quarter. Entropy Technologies LP now owns 5,504 shares of the company’s stock worth $251,000 after purchasing an additional 310 shares during the period. Rockefeller Capital Management L.P. increased its holdings in Artivion by 150.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after purchasing an additional 399 shares in the last quarter. Arizona State Retirement System increased its holdings in Artivion by 4.6% during the 4th quarter. Arizona State Retirement System now owns 11,235 shares of the company’s stock worth $512,000 after purchasing an additional 494 shares in the last quarter. Finally, Amundi raised its stake in shares of Artivion by 7.5% in the 1st quarter. Amundi now owns 7,186 shares of the company’s stock valued at $263,000 after purchasing an additional 501 shares during the period. Institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.